Trending...
- Chicago: Weekend Recap: Mayor Brandon Johnson Attends South Side Town Hall, Meets With Baltimore Mayor To Discuss Community Safety Strategies, Goes Viral Again
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink
- Dongsheng's Titanium Recycling Business Enters Aerospace Sector by 2025
AVENTURA, Fla. - illiNews -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on illi News
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on illi News
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on illi News
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- The AI CEO Partners with D3 Hockey News to Elevate the Voice of Division III Hockey Nationwide
- Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
- Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on illi News
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
- Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
- $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Year-Round Deals for Customers With Square Signs
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on illi News
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
- ONE DAY ONLY-Anne Nordhaus-Bike Paintings 11/1, The Other Art Fair
- Chicago: Mayor Brandon Johnson Hails Glock's Move to Discontinue Pistol Models Easily Modified with "Glock Switches"
- Heritage at South Brunswick's Townhome Models Coming Soon!
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink
- Genuine Smiles Unveils New User-Friendly Website
- New White Paper: Eliminate the Risk of Hydrogen Embrittlement
- Nusign Global Launch Event Concludes Successfully, Embarking on a New International Chapter
- Lift Solutions Holdings Announces Exclusive Distributorship for Advanced Camera and Sensor Products from Automate Matrix
- Political Division and Safety Concerns Drive Record Number of Americans to Seek "Golden Visas," La Vida Survey Finds
- Champagne Connection Releases: "Mindset, Movement, Mastery: The Keys to Destroying Diabetes
- The Citizens Commission on Human Rights of Florida Celebrates Volunteers and Community Partners at the 9th Annual Humanitarian Awards Banquet
- J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
- Words of Veterans & Veterans Growing America Collaboration
- Mature Athlete - Want Elite, Web-Based Nutrition and Training Coaching?
